Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | SOD1 | P00441 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295402 | 0.92 | ALDH1A1 (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL11050996 | 0.90 | KDM4E (0.60) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL14731232 | 0.89 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL5251060 | 0.89 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL9974699 | 0.87 | TSHR (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL8349049 | 0.87 | TSHR (0.65) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL8057463 | 0.86 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| 1,3-Dipropoxybenzene SCHEMBL73716 | 0.85 | KMT2A (0.63) | KDM4EMAPK1TSHRKMT2ADHFR | |
| SCHEMBL3027029 | 0.85 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 | |
| SCHEMBL13463064 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | DIC CORPORATION (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | DIC CORPORATION (JP) | 2020-10-01 | — | — | US | disclosed |
| US-9808447-B2 | Inhibitors of Rho associated protein kinases (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-9409868-B2 | Inhibitors of rho associated protein kinases (ROCK) and methods of use | H. Lee Moffin Cancer Center and Research Institute, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2014-11-13 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-4459186-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1984-07-10 | — | — | US | disclosed |
| US-4212710-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4212711-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4148696-A | Electrochemical oxidation of activated alkyl aromatic compounds | UOP INC. (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | KDM4E 2227/4885ALDH1A1 4543/4885SMN1; SMN2 3711/4885 |
| US-11760934-B2 | Polymerizable compound, and liquid crystal composition and liquid crystal display element in which the compound is used | SFXN1, SFXN3, SIK3 | KDM4E 4593/4885ALDH1A1 3883/4885SMN1; SMN2 4341/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | KDM4E 1016/4885ALDH1A1 780/4885SMN1; SMN2 4014/4885 |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | KDM4E 2085/4885ALDH1A1 1785/4885SMN1; SMN2 3912/4885 |
| US-20200308488-A1 | POLYMERIZABLE COMPOUND, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT IN WHICH THE COMPOUND IS USED | SFXN1, SFXN3, SIK3 | KDM4E 4593/4885ALDH1A1 3883/4885SMN1; SMN2 4341/4885 |
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | KDM4E 2227/4885ALDH1A1 4543/4885SMN1; SMN2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.